Static Media Expands Significant Footprint In Tech, Science, and Entertainment Verticals with Acquisition of TVLine and BGR

Veracyte reported that its Decipher Prostate test can predict which very high-risk nonmetastatic prostate cancer patients may benefit from adding abiraterone to ADT, based on a retrospective Phase III STAMPEDE analysis. The test's evidence base now extends to predicting treatment benefit, not just risk stratification.

ORIC Pharmaceuticals reported Phase 1b data for enozertinib in 1L EGFR atypical NSCLC, showing 84% systemic and 70% intracranial ORR. The company plans to start the Phase 3 Redwood-1 trial in 1H 2027. According to ORIC, this marks a transition to late-stage development for enozertinib.

ORIC Pharmaceuticals reported preclinical data indicating its drug rinzimetostat may improve sensitivity to androgen receptor inhibition in prostate cancer, supporting its ongoing Phase 3 trial. The company believes this supports the drug's use across various disease settings.

ORIC Pharmaceuticals presented preclinical and translational data at ESMO Congress 2026, showing that rinzimetostat, its prostate cancer drug, enhances sensitivity to androgen receptor inhibition. The data suggest potential advantages over EZH2 inhibitors, including maintained effectiveness against resistance mutations and a favorable safety profile. ORIC's chief scientific officer highlighted the drug's potential best-in-class profile and its ongoing evaluation in the Himalayas-1 Phase 3 trial.

ORIC Pharmaceuticals presented data showing its lung cancer drug, enozertinib, shrank brain tumors in 70% of assessed patients with EGFR atypical mutations. The company plans to start a global Phase 3 trial in 1H 2027, with enrollment including patients with untreated brain metastases. Enozertinib showed a favorable safety profile and meaningful systemic and intracranial antitumor activity.

Jefferies upgraded MSC Industrial (MSM) to Buy, raising its price target to $135. The firm cited improving fundamentals, expected volume growth, and margin expansion. MSM shares are down 15%, trading at $112.43. The company reported Q4 earnings of $1.45 per share, beating estimates, with revenue of $1.08 billion. Despite a $42 million impairment charge, analysts note potential challenges ahead.